Utility of immunohistochemical detection of high molecular weight cytokeratin for differential diagnosis of proliferative conditions of the prostate

Masaru Shin, Masaki Q Fujita, Yutaka Yasunaga, Tsuneharu Miki, Akihiko Okuyama, Katsuyuki Aozasa

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: Differential diagnosis of adenocarcinoma from other proliferative conditions in the prostate is often problematic. Immunohistochemistry using an antibody (34βE12) to high molecular weight cytokeratin, specifically present in basal cells of the prostate, could clearly demonstrate the presence or absence of these cells in the proliferating glands and thus provide an important clue in cancer diagnosis. Methods: To examine the utility of immunostaining using 34βE12, we examined 88 equivocal lesions. Twenty lesions with apparently benign and malignant features were added as controls. We compared the morphologic features of these lesions with their immunoreactivities toward 34βE12 on a personal computer display following storage on the MICROPHOT-FXA system. Results: Proliferating glands in all 20 benign lesions had 34βE12-reactive basal cells, but none of the malignant lesions did. The equivocal lesions were categorized on morphologic grounds into 2 groups: possibly benign and possibly malignant. Forty-five (51.1%) of the 88 equivocal lesions, were positive for 34βE12. These included 35 of the 45 (77.8%) possibly benign lesions and 10 of the 43 (23.3%) possibly malignant lesions. Among the equivocal lesions, 10 considered possibly benign on morphologic grounds showed negative reactivities, and 10 considered possibly malignant showed positive reactivities. Even through comparison on the computer display, no difference in morphology could be discovered between the negative and positive lesions in either group. Conclusion: Immunohistochemical procedures using 34βE12 are indispensable in the diagnosis of equivocal prostate lesions.

Original languageEnglish
Pages (from-to)237-242
Number of pages6
JournalInternational Journal of Urology
Volume5
Issue number3
Publication statusPublished - 1998
Externally publishedYes

Fingerprint

Keratins
Prostate
Differential Diagnosis
Molecular Weight
Microcomputers
Adenocarcinoma
Immunohistochemistry
Antibodies
Neoplasms

Keywords

  • 34βE12
  • High molecular weight cytokeratin
  • Pathological diagnosis
  • Prostatic adenocarcinoma

ASJC Scopus subject areas

  • Urology

Cite this

Utility of immunohistochemical detection of high molecular weight cytokeratin for differential diagnosis of proliferative conditions of the prostate. / Shin, Masaru; Fujita, Masaki Q; Yasunaga, Yutaka; Miki, Tsuneharu; Okuyama, Akihiko; Aozasa, Katsuyuki.

In: International Journal of Urology, Vol. 5, No. 3, 1998, p. 237-242.

Research output: Contribution to journalArticle

Shin, Masaru ; Fujita, Masaki Q ; Yasunaga, Yutaka ; Miki, Tsuneharu ; Okuyama, Akihiko ; Aozasa, Katsuyuki. / Utility of immunohistochemical detection of high molecular weight cytokeratin for differential diagnosis of proliferative conditions of the prostate. In: International Journal of Urology. 1998 ; Vol. 5, No. 3. pp. 237-242.
@article{8500c7f42ed344e8a32d035bdffdfb2a,
title = "Utility of immunohistochemical detection of high molecular weight cytokeratin for differential diagnosis of proliferative conditions of the prostate",
abstract = "Background: Differential diagnosis of adenocarcinoma from other proliferative conditions in the prostate is often problematic. Immunohistochemistry using an antibody (34βE12) to high molecular weight cytokeratin, specifically present in basal cells of the prostate, could clearly demonstrate the presence or absence of these cells in the proliferating glands and thus provide an important clue in cancer diagnosis. Methods: To examine the utility of immunostaining using 34βE12, we examined 88 equivocal lesions. Twenty lesions with apparently benign and malignant features were added as controls. We compared the morphologic features of these lesions with their immunoreactivities toward 34βE12 on a personal computer display following storage on the MICROPHOT-FXA system. Results: Proliferating glands in all 20 benign lesions had 34βE12-reactive basal cells, but none of the malignant lesions did. The equivocal lesions were categorized on morphologic grounds into 2 groups: possibly benign and possibly malignant. Forty-five (51.1{\%}) of the 88 equivocal lesions, were positive for 34βE12. These included 35 of the 45 (77.8{\%}) possibly benign lesions and 10 of the 43 (23.3{\%}) possibly malignant lesions. Among the equivocal lesions, 10 considered possibly benign on morphologic grounds showed negative reactivities, and 10 considered possibly malignant showed positive reactivities. Even through comparison on the computer display, no difference in morphology could be discovered between the negative and positive lesions in either group. Conclusion: Immunohistochemical procedures using 34βE12 are indispensable in the diagnosis of equivocal prostate lesions.",
keywords = "34βE12, High molecular weight cytokeratin, Pathological diagnosis, Prostatic adenocarcinoma",
author = "Masaru Shin and Fujita, {Masaki Q} and Yutaka Yasunaga and Tsuneharu Miki and Akihiko Okuyama and Katsuyuki Aozasa",
year = "1998",
language = "English",
volume = "5",
pages = "237--242",
journal = "International Journal of Urology",
issn = "0919-8172",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Utility of immunohistochemical detection of high molecular weight cytokeratin for differential diagnosis of proliferative conditions of the prostate

AU - Shin, Masaru

AU - Fujita, Masaki Q

AU - Yasunaga, Yutaka

AU - Miki, Tsuneharu

AU - Okuyama, Akihiko

AU - Aozasa, Katsuyuki

PY - 1998

Y1 - 1998

N2 - Background: Differential diagnosis of adenocarcinoma from other proliferative conditions in the prostate is often problematic. Immunohistochemistry using an antibody (34βE12) to high molecular weight cytokeratin, specifically present in basal cells of the prostate, could clearly demonstrate the presence or absence of these cells in the proliferating glands and thus provide an important clue in cancer diagnosis. Methods: To examine the utility of immunostaining using 34βE12, we examined 88 equivocal lesions. Twenty lesions with apparently benign and malignant features were added as controls. We compared the morphologic features of these lesions with their immunoreactivities toward 34βE12 on a personal computer display following storage on the MICROPHOT-FXA system. Results: Proliferating glands in all 20 benign lesions had 34βE12-reactive basal cells, but none of the malignant lesions did. The equivocal lesions were categorized on morphologic grounds into 2 groups: possibly benign and possibly malignant. Forty-five (51.1%) of the 88 equivocal lesions, were positive for 34βE12. These included 35 of the 45 (77.8%) possibly benign lesions and 10 of the 43 (23.3%) possibly malignant lesions. Among the equivocal lesions, 10 considered possibly benign on morphologic grounds showed negative reactivities, and 10 considered possibly malignant showed positive reactivities. Even through comparison on the computer display, no difference in morphology could be discovered between the negative and positive lesions in either group. Conclusion: Immunohistochemical procedures using 34βE12 are indispensable in the diagnosis of equivocal prostate lesions.

AB - Background: Differential diagnosis of adenocarcinoma from other proliferative conditions in the prostate is often problematic. Immunohistochemistry using an antibody (34βE12) to high molecular weight cytokeratin, specifically present in basal cells of the prostate, could clearly demonstrate the presence or absence of these cells in the proliferating glands and thus provide an important clue in cancer diagnosis. Methods: To examine the utility of immunostaining using 34βE12, we examined 88 equivocal lesions. Twenty lesions with apparently benign and malignant features were added as controls. We compared the morphologic features of these lesions with their immunoreactivities toward 34βE12 on a personal computer display following storage on the MICROPHOT-FXA system. Results: Proliferating glands in all 20 benign lesions had 34βE12-reactive basal cells, but none of the malignant lesions did. The equivocal lesions were categorized on morphologic grounds into 2 groups: possibly benign and possibly malignant. Forty-five (51.1%) of the 88 equivocal lesions, were positive for 34βE12. These included 35 of the 45 (77.8%) possibly benign lesions and 10 of the 43 (23.3%) possibly malignant lesions. Among the equivocal lesions, 10 considered possibly benign on morphologic grounds showed negative reactivities, and 10 considered possibly malignant showed positive reactivities. Even through comparison on the computer display, no difference in morphology could be discovered between the negative and positive lesions in either group. Conclusion: Immunohistochemical procedures using 34βE12 are indispensable in the diagnosis of equivocal prostate lesions.

KW - 34βE12

KW - High molecular weight cytokeratin

KW - Pathological diagnosis

KW - Prostatic adenocarcinoma

UR - http://www.scopus.com/inward/record.url?scp=0031812926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031812926&partnerID=8YFLogxK

M3 - Article

C2 - 9624554

AN - SCOPUS:0031812926

VL - 5

SP - 237

EP - 242

JO - International Journal of Urology

JF - International Journal of Urology

SN - 0919-8172

IS - 3

ER -